- Home
- TCMD vs FHTX Comparison
TCMD vs FHTX Comparison
Compare TCMD & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCMD
- FHTX
- Stock Information
- Founded
- TCMD 1995
- FHTX 2015
- Country
- TCMD United States
- FHTX United States
- Employees
- TCMD N/A
- FHTX N/A
- Industry
- TCMD Medical/Dental Instruments
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- TCMD Health Care
- FHTX Health Care
- Exchange
- TCMD Nasdaq
- FHTX Nasdaq
- Market Cap
- TCMD 344.2M
- FHTX 517.9M
- IPO Year
- TCMD 2016
- FHTX 2020
- Fundamental
- Price
- TCMD $14.50
- FHTX $7.55
- Analyst Decision
- TCMD
- FHTX Strong Buy
- Analyst Count
- TCMD 0
- FHTX 5
- Target Price
- TCMD N/A
- FHTX $16.00
- AVG Volume (30 Days)
- TCMD 134.5K
- FHTX 135.3K
- Earning Date
- TCMD 11-04-2024
- FHTX 11-04-2024
- Dividend Yield
- TCMD N/A
- FHTX N/A
- EPS Growth
- TCMD 9789.88
- FHTX N/A
- EPS
- TCMD 1.36
- FHTX N/A
- Revenue
- TCMD $281,544,000.00
- FHTX $35,185,000.00
- Revenue This Year
- TCMD $9.66
- FHTX N/A
- Revenue Next Year
- TCMD $11.09
- FHTX $15.40
- P/E Ratio
- TCMD $10.61
- FHTX N/A
- Revenue Growth
- TCMD 5.71
- FHTX 61.95
- 52 Week Low
- TCMD $9.70
- FHTX $2.70
- 52 Week High
- TCMD $16.95
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- TCMD 57.17
- FHTX 45.26
- Support Level
- TCMD $14.18
- FHTX $7.24
- Resistance Level
- TCMD $14.73
- FHTX $8.35
- Average True Range (ATR)
- TCMD 0.37
- FHTX 0.54
- MACD
- TCMD -0.01
- FHTX -0.06
- Stochastic Oscillator
- TCMD 77.88
- FHTX 43.20
About TCMD Tactile Systems Technology Inc.
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.